Guanylate Cyclase Receptor Agonist For Treatment Of Tissue Inflammation And Carcinogenesis

The invention provides a method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular...

Full description

Saved in:
Bibliographic Details
Main Authors SHAILUBHAI KUNWAR, NIKIFOROVICH GREGORY, JACOB GARY S
Format Patent
LanguageChinese
English
Published 11.08.2017
Subjects
Online AccessGet full text

Cover

More Information
Summary:The invention provides a method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of the guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestin
Bibliography:Application Number: CN201611201926